Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.
More info

FONDAZIONE MENARINI

A non-profit institution founded in 1976 to promote research...

GO TO SITE

MENARINI IN ASIA-PACIFIC

Find our companies

FEATURED

Latest News

January 30 2023

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Read More
September 20 2022

Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections

Read More
August 24 2022

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

Read More
August 11 2022

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Read More
August 02 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

Read More
© 2023 Menarini Asia-Pacific Pte Ltd | All rights reserved